ACTON, Mass. - Insulet (NASDAQ:PODD) Corporation (NASDAQ: PODD), a leading medical device company known for its tubeless insulin pump technology, announced the appointment of Ana Maria Chadwick as its new Executive Vice President, Chief Financial Officer, and Treasurer, set to take effect on April 22, 2024. This move concludes a comprehensive search by the company to fill the executive role.
Ana Maria Chadwick, who will be leaving her current role as Executive Vice President and CFO of Pitney Bowes (NYSE:PBI), brings over 30 years of experience in finance and operations to Insulet. Her tenure at GE, spanning more than 27 years, saw her in various leadership positions, including CEO and COO of GE Capital Global Legacy Solutions and CFO of GE Capital Energy Financial Services.
Jim Hollingshead, President and CEO of Insulet, expressed confidence in Chadwick's capabilities, emphasizing her track record as a versatile and accomplished executive with a deep understanding of capital markets, business strategy, and investor relations.
Chadwick's career has been marked by her leadership in financial reporting and her efforts to drive financial and operational efficiencies across the U.S., Latin America, and Europe. Her expertise extends to a comprehensive grasp of tax policy and business strategy.
In addition to her corporate roles, Chadwick is actively involved in governance and mentorship, serving on the board of directors for Dollar General (NYSE:DG) and LiveGirl, Inc., and chairing the Audit Committee and the Pitney Bowes ILC Bank in Utah.
Lauren Budden, who has been serving as Insulet's Interim CFO and Treasurer, will continue with the company as Group Vice President, Chief Accounting Officer, and Controller. Hollingshead thanked Budden for her exceptional leadership during the transition period.
Insulet, headquartered in Massachusetts, continues to innovate in the medical device sector with its Omnipod product platform, aiming to simplify the lives of people with diabetes through advanced insulin delivery systems. The company's flagship product, the Omnipod 5 Automated Insulin Delivery System, integrates with continuous glucose monitors and can be managed via smartphone or controller.
The information in this article is based on a press release statement from Insulet Corporation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.